Αρχική World News EMA Recommends Extension of Therapeutic Indications for Acalabrutinib World News EMA Recommends Extension of Therapeutic Indications for Acalabrutinib Από Ogkologos - 18 Ιουνίου, 2025 870 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ESMO Asia Congress 2024, Singapore, 6-8 December 27 Νοεμβρίου, 2024 Using a Mind-Body Connection to Help You Cope During Cancer: An... 11 Ιανουαρίου, 2024 Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS... 7 Ιουλίου, 2025 Population Mortality from NSCLC in the US Fell Sharply Due to... 19 Αυγούστου, 2020 Φόρτωση περισσοτέρων HOT NEWS Coping With Life After a Bone Marrow Transplant: A Survivor’s Story EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab Elucidating a Risk of Developing Second Primary Malignancy During and After... Animal Shelters Are Honoring Healthcare Workers By Naming Shelter Dogs After...